AnHorn Medicines Co., Ltd.
Update：2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
AnHorn’s flagship therapeutic modality is BIGPRO®, a bi‑functional ligand that induces targeted degradation of disease-causing proteins. Using their proprietary AIMCADD® platform (which integrates AI, bioinformatics, and medicinal chemistry), AnHorn rapid
Founded Year
2020
Unified Business No.
83523270
Status
Active
Number of Employees
0
Total Paid-in
Capital
422,059,200 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
AnHorn Medicines Co., Ltd., founded in 2020 and based in Taipei, is a biotech company that designs novel therapeutics using an AI-powered drug discovery platform (AIMCADD®). Their mission is to develop a new class of protein-degrading therapies (BIGPRO®)
